Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Have cancer.~* Taking opioid therapy for continued intractable pain.~* Experiencing less bowel movement frequency compared to that before the opioid treatment.~* Must meet the protocol-definition of opioid-induced constipation.~Exclusion criteria:~* Gastrointestinal or pelvic disorders known to affect gastrointestinal functions or induce bowel transit disorder and ileus.~* Subjects, who in the investigator's opinion, have gastrointestinal dysfunction predominantly due to causes other than the use of opioids.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Alvimopan 0.25 mg/yday (Type: EXPERIMENTAL): None
- Alviompan 0.5 mg/day (Type: EXPERIMENTAL): None
- Alvimopan 1 mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).